



-25-

CLAIMS

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

What is claimed is:

8. A pharmaceutical composition for stimulating sexual response in a mammal,
5 comprising a peptide and a pharmaceutically acceptable carrier, wherein said peptide is a free acid
or pharmaceutically acceptable salt thereof comprising a sequence selected from the group
consisting of His-Phe-Arg-Trp (SEQ ID NO:1), His-D-Phe-Arg-Trp, homologs of His-Phe-Arg-Trp
(SEQ ID NO:1) and homologs of His-D-Phe-Arg-Trp.

9. The pharmaceutical composition of claim 8, wherein said peptide is a cyclic peptide.

10. The pharmaceutical composition of claim 8, wherein said peptide has a terminal
carboxyl group.

11. The pharmaceutical composition of claim 8, wherein the peptide consists of the
15 sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

12. A method for stimulating sexual response in a mammal, comprising administering a
pharmaceutically sufficient amount of a composition comprising a peptide or pharmaceutically
acceptable salt thereof of the formula Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

13. The method of claim 12, wherein the mammal is a male.

14. The method of claim 12, wherein the mammal is a female.

15. The method of claim 12, wherein the pharmaceutically sufficient amount is at a dose
25 level that does not induce emesis or other deleterious side effects.

16. The method of claim of claim 12, wherein the composition further comprises a
pharmaceutically acceptable carrier.

17. The method of claim 12, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

5

18. The method of claim 17, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

19. The method of claim 18, wherein the aqueous buffer is a member selected from the
10 group consisting of saline and citrate buffer.

20. A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising peptide wherein said peptide is a free acid or pharmaceutically acceptable salt thereof comprising a sequence selected from the group
15 consisting of His-Phe-Arg-Trp (SEQ ID NO:1), His-D-Phe-Arg-Trp, homologs of His-Phe-Arg-Trp (SEQ ID NO:1) and homologs of His-D-Phe-Arg-Trp.

21. The method of claim 20, wherein the mammal is a male.

20 22. The method of claim 20, wherein the mammal is a female.

23. The method of claim 20, wherein the peptide consists of the sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

25 24. The method of claim of claim 20, wherein the composition further comprises a pharmaceutically acceptable carrier.

25. The method of claim 20, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration
30 through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

26. The method of claim 20, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

5 27. The method of claim 26, wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.